Takeda Pharmaceutical Company Limited (TAK)
Filed: 18 Dec 24, 6:01am
| [Cover] | |||||
| [Document Filed] | Extraordinary Report (Inline XBRL attached to the Amendment Extraordinary Report dated December 18, 2024) | ||||
| [Filed with] | Director, Kanto Local Finance Bureau | ||||
| [Filing Date] | September 26, 2024 | ||||
| [Company Name] | Takeda Pharmaceutical Company Limited | ||||
| [Title and Name of Representative] | Christophe Weber, Representative Director, President & Chief Executive Officer | ||||
| [Address of Head Office] | 1-1, Doshomachi 4-chome, Chuo-ku, Osaka (The above address is the registered head office location and the ordinary business operations are conducted at the “Nearest Place of Contact”) | ||||
| [Telephone Number] | Not applicable | ||||
| [Name of Contact Person] | Not applicable | ||||
| [Nearest Place of Contact] | 1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo (Global Headquarters) | ||||
| [Telephone Number] | +81-3-3278-2111 (Main telephone number) | ||||
| [Name of Contact Person] | Norimasa Takeda, Head of Global Consolidation and Japan Reporting, Global Finance | ||||
| [Please for public inspection] | Takeda Pharmaceutical Company Limited (Global Headquarters) (1-1, Nihonbashi Honcho 2-chome, Chuo-ku, Tokyo) Tokyo Stock Exchange, Inc. (2-1, Nihonbashi Kabutocho, Chuo-ku, Tokyo) Nagoya Stock Exchange, Inc. (8-20, Sakae 3-chome, Naka-ku, Nagoya) Fukuoka Stock Exchange (14-2, Tenjin 2-chome, Chuo-ku, Fukuoka) Sapporo Stock Exchange (14-1, Minamiichijonishi 5-chome, Chuo-ku, Sapporo) | ||||
| 1. | Reason for Submitting the Extraordinary Report | ||||||||||
| The Company has submitted the Extraordinary Report pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Law and Article 19, Paragraph 2, Item 3 of the Cabinet Office Ordinance concerning Disclosure of Corporate Affairs, etc. to report on resolution dated September 25, 2024, on a merger between specified subsidiaries that results in change to a status of the below specified subsidiary, and on the procedural changes related to this change of the specified subsidiary, resolved on December 17, 2024. | |||||||||||
| 2. | Details of the Extraordinary Report | ||||||||||
| (1) | Outline of specified subsidiaries | ||||||||||
| (a) | Company name | Shire Pharmaceuticals International Unlimited Company | |||||||||
| (b) | Headquarters | Block 2, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, D02 HW68 Republic of Ireland | |||||||||
| (c) | Name of representatives | Denis Anthony Ahern, Fiona Foley, Barbara Lenzlinger, Susan O’Reilly | |||||||||
| (d) | Capital | USD 6,891,886,042 | |||||||||
| (e) | Description of business | Shareholding of former Shire group entities | |||||||||
| (2) | Number of votes held prior to and after merger | ||||||||||
| (a) | Number of votes | ||||||||||
| Before merger | 6,891,886,042 votes (of which 6,891,886,042 votes owned indirectly) | ||||||||||
| After merger | 0 votes | ||||||||||
| (b) | Voting rights ownership ratio | ||||||||||
| Before merger | 100.0 % (of which 100.0 % owned indirectly) | ||||||||||
| After merger | 0.0% | ||||||||||
| (3) | Reason for change and date of liquidation | ||||||||||
| (a) | Reason for change | ||||||||||
| The Company has decided to dissolve Shire Pharmaceuticals International Unlimited Company, which is a specified subsidiary, through liquidation. | |||||||||||
| (b) | Date of liquidation | ||||||||||
| The administrative and legal processes of the liquidation will commence in due course in compliance with local regulations, however, the date of completion cannot be determined yet. | |||||||||||